Results 81 to 90 of about 32,827 (233)

USP10/XAB2/ANXA2 axis promotes DNA damage repair to enhance chemoresistance to oxaliplatin in colorectal cancer

Journal of Experimental & Clinical Cancer Research
Background Oxaliplatin-based chemotherapy is the first-line treatment for colorectal cancer (CRC). However, oxaliplatin resistance remains a major challenge contributing to treatment failure and poor prognosis. An increased capacity for DNA damage repair
Xingwu Liu, Shaoming Zhang, Yue An, Boyang Xu, Guanyu Yan, Mingjun Sun   +5 more
doaj   +1 more source

The Role of microRNAs in Regulating Cancer Cell Response to Oxaliplatin-Containing Regimens

Technology in Cancer Research & Treatment, 2023
Oxaliplatin (cyclohexane-1,2-diamine; oxalate; platinum [2+]) is a third-generation chemotherapeutic drug with anticancer effects. Oxaliplatin has a role in the treatment of several cancers.
Ali Tavakoli Pirzaman MD, Manijeh Ebrahimzadeh Pirshahid MD, Bahareh Babajani MS, Amirhossein Rahmati MS, Shokat Niknezhad MS, Rezvan Hosseinzadeh MD, Mehdi Taheri MS, Faezeh Ebrahimi-Zadeh MD, Shahrbanoo Doostmohamadian MS, Sohrab Kazemi PhD   +9 more
doaj   +1 more source

PANX2 Suppresses Lung Adenocarcinoma Progression by Inducing Disulfidptosis and Enhancing Antitumor Immunity

Advanced Science, EarlyView.
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen, Zhao‐Yu Liu, Gao‐Wen Qu, Run‐Hao Zeng, Wen‐Xia Yao, Yong‐Bing Zhou, Xue Liang, Yu‐Xiong Lai   +7 more
wiley   +1 more source

Lnc-RP11-536 K7.3/SOX2/HIF-1α signaling axis regulates oxaliplatin resistance in patient-derived colorectal cancer organoids

Journal of Experimental & Clinical Cancer Research, 2021
Background Resistance to oxaliplatin is a major obstacle for the management of locally advanced and metastatic colon cancer (CC). Although long noncoding RNAs (lncRNAs) play key roles in CC, the relationships between lncRNAs and resistance to oxaliplatin
Qingguo Li, Huizhen Sun, Dakui Luo, Lu Gan, Shaobo Mo, Weixing Dai, Lei Liang, Yufei Yang, Midie Xu, Jing Li, Peiyong Zheng, Xinxiang Li, Yan Li, Ziliang Wang   +13 more
doaj   +1 more source

ANXA2+ Small Extracellular Vesicles Drive Chemoresistance in Anaplastic Thyroid Cancer by Promoting XRCC5 Lactylation and Enhancing Non‐Homologous End‐Joining Repair

Advanced Science, EarlyView.
ANXA2+ sEVs promote cisplatin resistance in ATC by stabilizing the SRC/LDHA interaction, increasing LDHA phosphorylation and activity, and lactate production. Elevated lactate levels promote KAT5‐mediated lactylation of XRCC5 at lysine 265, enhancing its binding to XRCC6.
Shanshan Su, YiShan Xiong, Yuxuan Liang, Xiang Min, Daofeng Dai   +4 more
wiley   +1 more source

A Randomized Phase II Study of Subcutaneous Mosunetuzumab in Combination With Polatuzumab Vedotin Compared With Rituximab Plus Polatuzumab Vedotin in Patients With Relapsed or Refractory Large B‐Cell Lymphoma

American Journal of Hematology, EarlyView.
ABSTRACT Mosunetuzumab plus polatuzumab vedotin has shown promising activity versus rituximab plus polatuzumab vedotin (R‐Pola) in patients with relapsed/refractory (R/R) large B‐cell lymphoma (LBCL; NCT03671018). We present results from the Phase II randomized cohort, evaluating subcutaneous mosunetuzumab plus polatuzumab vedotin (Mosun‐Pola), with ...
Julio C. Chavez, Mariana Bastos‐Oreiro, Catherine Diefenbach, Izidore S. Lossos, Nirav Shah, Sarit Assouline, Adam J. Olszewski, Seema Naik, Nilanjan Ghosh, Song Pham, Michael C. Wei, Connie Batlevi, Iris To, Wahib Ead, Sneha Makadia, Elicia Penuel, Jing Jing, Lihua E. Budde   +17 more
wiley   +1 more source

miR-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity

Cellular Physiology and Biochemistry, 2018
Background/Aims: Although oxaliplatin is one of the most effective chemotherapeutic drugs used to treat colorectal cancer (CRC), long-term administration usually induces acquired drug resistance during the course of treatment.
Yongqiang Hua, Yaodong Zhu, Jijie Zhang, Zhenfeng Zhu, Zhouyu Ning, Hao Chen, Luming Liu, Zhen Chen, Zhiqiang  Meng   +8 more
doaj   +1 more source

Mechanism of Overcoming Oxaliplatin Resistance Using HT29 Subcloning [PDF]

, 2020
Abstract Background: Cancer cells are different from normal healthy cells even though they reside within the same tissue and adapt to others. This intra-tumoral heterogeneity is the reason for chemo-resistance, and the emergence of one or more clones, which are resistant to chemotherapeutic drugs, causing clonal outgrowth to form recurrent ...
Jisu Lee, MI YOON KIM, Woomi Yang, Il-woung Kim, Seung-Kiel Park, Jong-Il Park   +5 more
openaire   +1 more source

Therapeutic Applications of Stimuli‐Based Release and Engineering of Extracellular Vesicles

Advanced NanoBiomed Research, EarlyView.
This review summarizes the effects of endogenous and exogenous stimuli, their effects on the natural release of extracellular vesicles, as well as their uptake and release. It also gives an overview of stimuli‐responsive EVs and their therapeutic applications. Extracellular vesicles (EVs), nano‐ to microsized lipid bilayer membrane‐bound particles, are
Gloria Kemunto, Kristen Dellinger
wiley   +1 more source

Dragon (RGMb) induces oxaliplatin resistance in colon cancer cells

Oncotarget, 2016
Colorectal cancer (CRC) is one of the most commonly diagnosed cancers and a major cause of cancer mortality. Chemotherapy resistance remains a major challenge for treating advanced CRC. Therefore, the identification of targets that induce drug resistance is a priority for the development of novel agents to overcome resistance.
Shi, Ying, Huang, Xiao-Xiao, Chen, Guo-Bin, Wang, Ying, Zhi, Qiang, Liu, Yuan-Sheng, Wu, Xiao-Ling, Wang, Li-Fen, Yang, Bing, Xiao, Chuan-Xing, Xing, Hui-Qin, Ren, Jian-Lin, Xia, Yin, Guleng, Bayasi   +13 more
openaire   +3 more sources